The Historical Past For VX-809

Compared with men who were younger than the median age of 73 years, men aged ��73 years with localized prostate cancer who received brachytherapy and NHT had an increased risk of ACM compared with men who did not receive NHT. Cancer 2010. ? 2010 American Cancer Society. Prostate brachytherapy is used often for the treatment of men with localized prostate cancer. In patients who receive brachytherapy, the use of neoadjuvant androgen-deprivation therapy (ADT) has become more common increasingly over the past 2 decades.1 The rationale for it use includes an effort to reduce prostate volume before brachytherapy, to improve urinary flow, or to take advantage of the possible synergistic effects expected when hormone suppression and radiation are used. However, it has not been established that androgen deprivation improves the outcomes http://www.selleckchem.com/products/17-AAG(Geldanamycin).html of patients with low-risk disease, yet androgen deprivation may have a negative impact on cardiovascular health.2-4 Therefore, understanding the impact of its use in these patients is important, and the results and consequences of ADT are worthy of further clinical research. Specifically, discrepancy exists in the literature regarding the impact of neoadjuvant hormone therapy (NHT) on the risk of all-cause mortality (ACM) in men who receive prostate brachytherapy for localized prostate cancer. In 1 study, men with a median age of 73 years had an increased risk of ACM with the use of NHT,5 whereas this increased risk was not noted in a second study of men with a median http://www.selleckchem.com/products/lgk-974.html age of 67 years.6 Therefore, the objective of the current study was to examine the effect of NHT on the risk of ACM in men with localized prostate cancer who were treated with brachytherapy within the 21st Century Oncology Consortium in an age-adjusted and stratified analysis. Between May 1991 and September 2005, 7166 men with localized prostate cancer were received brachytherapy at 20 centers within the 21st Century Oncology Consortium. Pretreatment and follow-up information for these patients was collected prospectively in a database maintained by 21st Century Oncology. The records of these men were reviewed retrospectively. This study was approved under Institutional Review Board Protocol 1087891. Patients were excluded if they received supplemental external-beam radiation (n = 3744) or if they had http://www.selleck.cn/products/VX-809.html years) who had localized prostate cancer that was treated with brachytherapy and no supplemental external-beam radiation therapy. Low-risk, intermediate-risk, and high-risk disease according to the risk categorization system defined by D'Amico et al was present in 65%, 23%, and 12% of men, respectively.7 Table 1 shows the baseline characteristics of the patient population stratified according to the median age73 and the use of ADT. All men were treated with ultrasound-guided brachytherapy using iodine-125 or palladium-103 sources.